Core Insights - Tian Gong International (00826) hosted a visit from Baris Telseren, President of Bodycote Corporate Growth, to discuss future strategic cooperation [1] - Bodycote is a leading global company in heat treatment and hot isostatic pressing (HIP) technology, serving high-end manufacturing sectors such as aerospace, military, automotive, energy, and medical [3] - Tian Gong International has over 40 years of experience in the materials field and has established a complete powder metallurgy industry chain, with forward-looking layouts in emerging fields like new energy vehicles and nuclear fusion energy [3] Group 1 - Bodycote operates 150 factories across 21 countries and is one of the earliest global suppliers of heat treatment services for the aerospace industry [3] - Bodycote's advanced equipment features precise temperature and pressure control systems, significantly enhancing the strength, wear resistance, corrosion resistance, and lifespan of metal components [3] - Tian Gong International is planning a second phase project for its Jiangsu Tian Gong Xin Zhi Materials Co., Ltd., which will add five new hot isostatic pressing devices [3] Group 2 - The collaboration between Tian Gong International and Bodycote aims to leverage both companies' core strengths, potentially achieving a win-win situation in the powder metallurgy and heat treatment sectors [4] - The open discussions have deepened the strategic cooperation consensus and clarified new directions and paths for business expansion [4] - Both companies plan to fully collaborate in domestic and international powder metallurgy and heat treatment businesses, enhancing service capabilities for end customers and promoting the international transformation of China's high-end manufacturing industry [4]

Group 1 - The "Film+" consumption pilot program aims to enhance the film industry's role in driving consumption growth and transforming it into a diversified consumption ecosystem [1] - Sixteen cities have been selected as pilot cities for the "Film+" initiative, including Beijing, Shanghai, and Shenzhen, focusing on increasing film viewing consumption and innovating cinema experiences [1] - The program will explore new consumption models and extend the film industry's value chain, promoting a healthy cultural environment and meeting the growing demand for quality life among the public [1] Group 2 - The pre-sale for the 2026 Spring Festival film season has officially started, with films like "Silent Awakening" and "Bounty Hunter: Winds Rise in the Desert" leading the box office [2] - As of the latest data, the pre-sale box office for the 2026 Spring Festival has exceeded 160 million yuan, setting a positive tone for the upcoming film season [2] Group 3 - Companies involved in the Hong Kong film and entertainment industry chain include Damai Entertainment, Maoyan Entertainment, IMAX China, and China Ruyi [3]

2月13日，深交所发布公告，因沃尔核材（002130）(09981)在香港联合交易所有限公司上市不适用价格稳定期机制，且相应A股上市满10个交易日，根据 《深圳证券交易所深港通业务实施办法》的有关规定，港股通标的证券名单发生调整，调入沃尔核材，并自2026年02月13日起生效。 | 代码 | 简称 | 调整方向 | | --- | --- | --- | | 09981 | 沃尔核材 | 调 | ...

2月12日，中石化炼化工程发布公告，香港联交所上市委员会已于近期就中国石油集团持有的约2.2亿股 内资股转换的H股(经转换H股)上市及买卖授出上市批准。约2.2亿股内资股已于2026年2月12日完成转换 为H股。经转换H股将于2026年2月13日上午九时正开始于香港联交所上市。 香港联交所最新资料显示，2月12日，中石化炼化工程(02386)股东将股票存入中国证券登记结算香港， 存仓市值16.98亿港元，占比15.42%。 ...

此前烯石电车新材料发布公告，于2026年2月3日，公司全资附属公司Allied Apex已与创驰其中一名股东 严博订立买卖协议，据此Allied Apex将会向严博收购创驰40%已发行股本，代价为现金150万港元。 智通财经APP获悉，香港联交所最新资料显示，2月12日，烯石电车新材料(06128)股东将股票由昌利证 券转入ABN AMRO Clearing Hong Kong Limited，转仓市值575.03万港元，占比7.45%。 ...

香港联交所最新资料显示，2月12日，凌锐控股(00784)股东将股票存入佳富达证券，存仓市值1973.79万 港元，占比12.65%。 凌锐控股公布截至2025年9月30日止6个月中期业绩，收益为9140.6万港元，同比减少24.2%；净利31.1 万港元，同比减少79.88%；每股盈利0.04港仙。 ...

公司简介 招股书显示，引航生物是以技术创新为驱动的合成生物学引领者，致力于提供绿色可持续、高效生产且具备突出成本优势的生物基产品。公司的产品已在相 关市场占据领先地位。 据港交所2月12日披露，苏州引航生物科技股份有限公司(简称：引航生物)向港交所主板递交上市申请，华泰国际为其独家保荐人。 就原料药及中间体而言，根据灼识咨询，自2025年实现氟苯尼考的规模化生产后，以截至2025年9月30日止九个月的收入计，公司于同期的市场份额为 24.5%，位居全球氟苯尼考行业第二位；以截至2025年9月30日止九个月的收入(包括内部及外部销售)计算，公司的D-乙酯市场份额44.5%，位居全球D-乙酯 行业排名第一。 为支持产品创新与商业化，引航生物已构筑起"双引擎"研发能力，包括突破性原创工艺路线设计能力及基于AI辅助与高通量DBTL工作流程的高效合成生物 学工程化能力。原创工艺路线设计为目标化合物的开发奠定有商业可行性的适宜技术路径，而高效的合成生物学工程化能力可在实验室快速完成酶及菌株改 造，并推动规模化生产。这两者结合在一起，使公司能够持续开发出有竞争力的产品并保持高速增长。 引航生物的产品开发遵循技术驱动模式，基 ...

Group 1 - The core viewpoint of the article highlights the recent stock transfer of Hongshengchang Resources (01850) from KGI Securities Asia to Cathay Securities (Hong Kong), with a market value of HKD 16.8564 million, representing 10.72% of the total shares [1] - For the six months ending October 31, 2025, Hongshengchang Resources reported revenue of approximately HKD 269 million, reflecting a year-on-year decrease of 1.0% [1] - The company experienced a loss attributable to shareholders of HKD 2.97 million, marking a shift from profit to loss compared to the previous year, with a loss per share of HKD 0.0172 [1]

香港联交所最新资料显示，2月12日，梦金园(02585)股东将股票存入中国证券登记结算香港，存仓市值 6.4亿港元，占比17.17%。 梦金园公布，4000万股非上市股份已于2026年2月12日完成转换为H股。已转换H股将于2026年2月13日 上午九时正开始在联交所上市及交易。 ...

Group 1 - The core point of the article is that CMON has successfully completed a share placement agreement, with a total of 10.32 million shares being placed at a price of HKD 0.9500 per share, representing approximately 16.67% of the company's enlarged issued share capital after the placement [1] - The shares were deposited into the Metaverse (International) Securities, with a total market value of HKD 15.48 million, accounting for 20% of the shares [1] - All conditions outlined in the placement agreement have been met, and the placement was completed on February 12, 2026 [1]